FDA approves Zenbexus, first-in-class therapy for advanced multiple myeloma
The FDA approved Bristol Myers Squibb's oral iberdomide (Zenbexus) for advanced multiple myeloma in combination with Darzalex and dexamethasone, marking the debut of a new drug class and the use of a more sensitive measure of cancer remission.